What I am working with: ten weeks · a GLP-1 receptor agonist.
This has the shape of a fact but I cannot find its origin.
What I found instead were three secondary sources all citing each other.
Has anyone verified this independently?
The relevant arithmetic is that steady state takes four to five half-lives, so a one-week half-life means a four-week step interval and nothing shorter is informative.
Liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.
| Agent | Start | Step interval | Maintenance range | Max studied |
|---|---|---|---|---|
| Semaglutide (weight management) | 0.25 mg/wk | 4 weeks | 1.7–2.4 mg/wk | 2.4 mg/wk |
| Semaglutide (T2DM) | 0.25 mg/wk | 4 weeks | 0.5–2.0 mg/wk | 2.0 mg/wk |
| Tirzepatide | 2.5 mg/wk | 4 weeks | 5–15 mg/wk | 15 mg/wk |
| Liraglutide (weight management) | 0.6 mg/day | 1 week | 3.0 mg/day | 3.0 mg/day |
| Oral semaglutide | 3 mg/day | 4 weeks | 7–14 mg/day | 50 mg/day (trial) |
Structure is identical across the class: small start, four-week steps, a defined maintenance range, a defined ceiling.
It helps to be literal here: escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.
Trial data show gastrointestinal adverse events concentrated in the escalation phase and declining at stable doses.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Slower costs time and nothing else. The ceiling is the same.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsAnswering this needs the agent and the current step, since the schedules differ and the reason they differ is pharmacokinetic.
The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.
The part that matters: titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.
A schedule described here is a published schedule for a licensed product and is not a recommendation.
Stepping back is a normal adjustment, not a failure.
edited 6 May 2025 by aine_mulcahy — added the citation requested in comments
This is the single most consequential controllable variable in the whole experience, and people routinely rush it.
Holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.
The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.
Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.
The caveat is that titration decisions belong with a clinician who knows what else is on board.
Hold rather than escalate while symptoms are active. Always.
Worth being precise here: the initiation step in most schedules is not intended to be therapeutic; it is there to introduce the receptor to the drug.
For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.
Faster titration does not reach the destination sooner in any way that matters; it reaches the symptoms sooner.
Four half-lives between steps, minimum. Work it out for your agent.
The honest answer is that going slower costs time and nothing else, since the exposure ceiling is unchanged.
The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.
Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.
The caveat that matters: dose decisions on a licensed medicine belong with a prescriber, and dose decisions on research-use-only material belong to a category where nobody has any obligation to you at all.
The top of the schedule is not the target. The working dose is.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.